2 September 2025 in BMC Musculoskeletal Disorders
To assess research directions of the Mesenchymal stem cells (MSCs) injections in traumatology and orthopaedics. The study monitored the protocols of randomised controlled trials (RCTs) and systematic reviews (SRs) investigating mesenchymal stem cell (MSC) injections for various traumatological and orthopaedic conditions. Relevant RCT protocols were identified through searches of ClinicalTrials.gov, International Clinical Trials Registry Platform, EU Clinical Trials Register databases for RCTs and SRs were obtained from PROSPERO. The databases were searched from their inception to December 2023. A total of 449 clinical trials were identified. At the time of the study, 159 (35.4%) trials had been completed, and only 56 (12.5%) had published results in peer-reviewed journals. Data on clinical trial completion were normally distributed (p = 0.145). The duration for trial completion was 40.6 ± 26.5 months (range: 1 to 153 months). The most commonly investigated indications for MSCs injections were osteoarthritis of the hip and knee (37.6%) and spinal cord injuries (10.5%). The most frequent sources of MSCs were bone marrow (26.5%), adipose-derived (20.5%) and umbilical cord (15.4%). Reported MSCs concentrations varied widely, ranging from 0.5 × 10⁶ to 9.7 × 10⁸ cells. The most frequently used concentrations were 1 × 10⁷ (8.2%), 2 × 10⁷ (8.0%), 5 × 10⁷ (5.8%), and 10 × 10⁷ (5.8%) cells, while 59 other dosing schemes were each used in fewer than 1% of trials. Furthermore, 55.5% of protocols did not specify the cell concentration. A search in PROSPERO identified 114 systematic review protocols. By the time of the study, 32 studies (28.10%) had been completed, with the results of 30 (26.32%) published in peer-reviewed journals. MSC injections represent a growing area of research in traumatology and orthopaedics. However, the results of only a small proportion of clinical trials and systematic reviews are published in peer-reviewed journals, which most likely does not allow practitioners to form a full judgement on the efficacy and safety of this treatment.
28 November 2023 in Journal of Human Kinetics
The prevalence of the Relative Age Effect (RAE) was studied among medalists from the World Athletics Championships at U18, U20 and Senior age groups and from the Olympic Games from 2000 to 2022. The specific events examined were the 100, 200, 400, 800, 1500, and 3000/5000 m, the long jump, the triple jump, the high jump and the pole vault. Dates of birth from 1,858 outdoor track and field athletes were analysed and further divided into four groups according to the quartile of birth. The RAE was found to be widespread among athletes of both sexes in U18 and U20 age groups in all examined disciplines. There was no difference between the most successful U18 and U20 athletes (p = 0.52). Among senior athletes of both sexes, this effect was not detected and the number of "late-born" athletes in this age group was higher than athletes born in the first three quarters. The prevalence of the RAE across the four groups of events was found in U18 and U20 age groups. Additionally, within each age group, the difference among events was statistically significant. In most successful track and field athletes, the RAE is only significant in U18 and U20 age groups. In senior athletes, the number of "late-born" athletes is significant while RAE disappears. These data may be considered when assessing the athletic potential of an individual athlete.